Literature DB >> 21584767

Insulin therapy.

Monika Lechleitner1, Friedrich Hoppichler.   

Abstract

Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus. In type 2 diabetes, insulin is indicated if glycaemic goals are not reached by oral anti diabetics, as well as for metabolic detoriation, co-morbidities, surgery, pregnancy or contradictions against oral anti diabetics. Insulin preparations are characterized by the onset of the insulin action, the peak profile and duration of action. Available are short acting, long-acting and premixed preparations of human insulin, and insulin analogues. The gold standard of insulin therapy in type 1 diabetes is functional insulin therapy with a basal-bolus insulin regimen and control and adaption of the therapy by the patient. Various insulin regimens are available for treating patients with type 2 diabetes, including basal insulin supported oral therapy, supplementary mealtime injection of short acting insulin or insulin analogues, conventional insulin therapy or a basal bolus procedure. The various insulin preparations and regimens make it possible to adapt the therapy according to the patient's individual need.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21584767     DOI: 10.1007/s10354-011-0889-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  31 in total

Review 1.  Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

Authors:  A Siebenhofer; J Plank; A Berghold; M Narath; R Gfrerer; T R Pieber
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 2.  An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.

Authors:  Katarina Raslova
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

3.  Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.

Authors:  Edoardo Mannucci; Matteo Monami; Daniela Balzi; Barbara Cresci; Laura Pala; Cecilia Melani; Caterina Lamanna; Ilaria Bracali; Michela Bigiarini; Alessandro Barchielli; Niccolo Marchionni; Carlo Maria Rotella
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 17.152

4.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

5.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

6.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 7.  Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.

Authors:  Arturo Rolla
Journal:  Am J Med       Date:  2008-06       Impact factor: 4.965

Review 8.  Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.

Authors:  Therese M Chapman; Stuart Noble; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Insulin glulisine. Aventis Pharma.

Authors:  Daniela Barlocco
Journal:  Curr Opin Investig Drugs       Date:  2003-10

Review 10.  Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.

Authors:  A N Goudswaard; N J Furlong; G E H M Rutten; R P Stolk; G D Valk
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18
View more
  1 in total

1.  A Dioxidovanadium Complex cis-[VO2 (obz) py] Attenuates Hyperglycemia in Streptozotocin (STZ)-Induced Diabetic Male Sprague-Dawley Rats via Increased GLUT4 and Glycogen Synthase Expression in the Skeletal Muscle.

Authors:  Bonisiwe Mbatha; Andile Khathi; Ntethelelo Sibiya; Irvin Booysen; Phikelelani Ngubane
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-31       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.